UNSPSC 51332103: Levosulpiride or sulpiride

This classification denotes a dopamine antagonist with the molecular formula C15H23N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7MNE9M8287, chemically known as o-anisamide, n-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-, (s)-(-)- but generally known as sulpiride, which bears US NIH Compound Identifier 5355. European Medicines Agency schedules Sulpiride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10758MIG.

UNSPSC 51332103 Levosulpiride or sulpiride is a Commodity code. The recent state and local opportunities tagged under this code show little alignment with levosulpiride or sulpiride specifically; instead, they reflect broader pharmaceutical procurement activity spanning emergency-response medications (naloxone), generic multi-source drug programs, and pharmacy benefit program restructuring. State and local governments are using this code space to procure pharmaceuticals across three distinct contexts: direct acquisition of naloxone and drug deactivation systems for community health initiatives, establishment of cooperative purchasing contracts for generic drugs and over-the-counter products distributed through authorized wholesalers to participating government facilities, and exploratory requests for information on direct-to-manufacturer prescription arrangements designed to reduce costs and improve fulfillment efficiency outside traditional pharmacy benefit manager channels. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance / MMCAP, serving Minnesota, Oregon, and participating jurisdictions). These issuers span direct government procurement, state agency pharmacy programs, and cooperative purchasing arrangements for participating municipalities and counties.

Recent activity is concentrated in Florida, Texas, and the MMCAP region (Minnesota and Oregon). The Seminole County IFB posted June 30, 2026, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline (note: date conflict in source) and quarterly delivery to the Seminole County Community Health Building in Sanford. The Texas HHS Commission issued RFI HHS0017013 in April 2026 as exploratory market intelligence for direct-to-manufacturer prescription programs serving state employee and retiree plans, with no binding procurement timeline. MMCAP's RFP S1070000015802, posted January 20, 2026 with a March 26, 2026 response deadline, establishes multi-award contracts for generic pharmaceuticals and OTC products to be distributed across participating state and local government facilities through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), with awarded contracts effective July 1, 2026. The MMCAP procurement emphasizes price competitiveness (75 percent of evaluation weight), compliance with cGMP and DSCSA, and flexible pricing models; vendors must maintain $5,000,000 commercial general liability coverage and agree to a 3 percent administrative fee.